<https://helda.helsinki.fi>

The Effects of Vitamin D Supplementation During Infancy on Growth During the First 2 Years of Life

Hauta-Alus, Helena H.

2021-03

Hauta-Alus , H H , Holmlund-Suila , E M , Kajantie , E , Rosendahl , J , Valkama , S M , Enlund-Cerullo , M , Andersson , S & Mäkitie , O 2021 , ' The Effects of Vitamin D Supplementation During Infancy on Growth During the First 2 Years of Life ' , Journal of Clinical Endocrinology and Metabolism , vol. 106 , no. 3 , pp. E1140-E1155 . <https://doi.org/10.1210/clinem/dgaa943>

<http://hdl.handle.net/10138/337884>

<https://doi.org/10.1210/clinem/dgaa943>

---

unspecified

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

The Effects of Vitamin D Supplementation During Infancy on Growth During the First Two Years of Life

Helena H. Hauta-alus^{1,2,3}, Elisa M. Holmlund-Suila^{1,2}, Eero Kajantie^{1,3,4,5}, Jenni Rosendahl^{1,2}, Saara M. Valkama^{1,2}, Maria Enlund-Cerullo^{1,2}, Sture Andersson¹, Outi Mäkitie^{1,6,7}

¹ Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

² Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland

³ Finnish Institute for Health and Welfare (THL), Helsinki, Finland

⁴ PEDEGO Research Unit, MRC Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland

⁵ Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

⁶ Department of Molecular Medicine and Surgery, Karolinska Institutet, and Clinical Genetics, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden

⁷ Folkhälsan Institute of Genetics, Helsinki, Finland

Short title: Vitamin D and early childhood growth

Keywords: vitamin D supplementation, 25-hydroxyvitamin D, maternal, infant, early childhood growth, clinical trial

Corresponding author and person whom reprint requests should be addressed:

Helena Henrietta Hauta-alus, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Biomedicum 2 C, P.O. Box 705, 00020 HUS, Finland. Tel +358 947175731.

24 Email helena.hauta-alus@helsinki.fi.

25 Grants supporting the writing of the paper: Päivikki and Sakari Sohlberg Foundation, Juho Vainio

26 Foundation, European Commission (Horizon 2020), Academy of Finland, Foundation for Pediatric

27 Research, Signe and Ane Gyllenberg Foundation, Sigrid Juselius Foundation, Novo Nordisk

28 Foundation, Foundation for Cardiovascular Research, Diabetes Research Foundation, Finska

29 Läkaresällskapet, A Special Governmental Subsidy for Clinical Research, Folkhälsan Research

30 Foundation, Pediatric Research Center and Orion Research Foundation.

31 Disclosure summary: The authors have nothing to disclose.

32 The project protocol is registered at ClinicalTrials.gov: NCT01723852.

33

34

Abstract

Context. The relationship between maternal and infant vitamin D and early childhood growth remains inadequately understood.

Objective. To investigate how maternal and child 25-hydroxyvitamin D [25(OH)D] and vitamin D supplementation impact growth during the first 2 years of life.

Design. A randomized, double-blinded intervention study.

Setting. A single-center study from pregnancy until offspring age 2 years.

Participants. Altogether 812 term-born children with complete data, recruited at Maternity Hospital.

Intervention. Children received daily vitamin D₃ supplementation 10 µg (Group-10) or 30 µg (Group-30) from age 2 weeks to 2 years.

Main outcome measures. Anthropometry and growth rate at age 1 and 2 years.

Results. Toddlers born to mothers with Pregnancy 25(OH)D >125 nmol/L were at 2 years lighter and thinner than the reference group with 25(OH)D 50-74.9 nmol/L ($P<0.010$). Mean 2-year 25(OH)D concentrations were 87 nmol/L in Group-10 and 118 nmol/L in Group-30 ($P<0.001$). When Group-30 was compared with Group-10, difference in body size was not statistically significant ($P>0.053$), but Group-30 had slower growth in length and head circumference between 6 months and 1 year ($P<0.047$), and more rapid growth in weight and length-adjusted weight between 1 and 2 years ($P<0.043$). Toddlers in the highest quartile of 25(OH)D (>121 nmol/L) were shorter (mean difference 0.2 SD score (SDS), $P=0.021$), lighter (mean difference 0.4 SDS, $P=0.001$) and thinner (in length-adjusted weight) (mean difference 0.4 SDS, $P=0.003$) compared with the lowest quartile (<81.2 nmol/L).

Conclusion. Vitamin D and early childhood growth may have an inverse U-shaped relationship.

58 Introduction

59 Vitamin D has a vital role in childhood growth and development and chronic and severe vitamin D
60 deficiency leads to rickets, stunted growth and delayed neuromuscular development (1). Maternal
61 vitamin D deficiency may increase the likelihood of pregnancy complications and prenatal growth
62 restriction (2–4). Vitamin D status is defined by blood 25-hydroxyvitamin D concentration
63 [25(OH)D], which is generally considered sufficient at values at or above 50 nmol/L (1,5,6). Vitamin
64 D insufficiency (25(OH)D below 50 nmol/L) is common worldwide (7,8), the prevalence ranging
65 from 7% in Northern Europe to 90% in the Middle East (5). Especially populations with inadequate
66 sunlight exposure are at an increased risk. In addition to endogenously produced vitamin D in the
67 skin, diet and supplements are important sources of vitamin D.

68 A global consensus recommendation for prevention of vitamin D deficiency rickets was published in
69 2016 (1). The recommended vitamin D supplementation was a daily dose of 15 µg for pregnant
70 women and 10 µg for infants (1). The latest guidelines given by the Finnish national health authorities
71 in 2018 recommend a daily total intake of 10 µg for pregnant women and infants (9). WHO does not
72 recommend vitamin D supplementation for pregnant women (10). Some researchers consider the
73 target 25(OH)D level to be much higher than 50 nmol/L, preferably >75-100 nmol/L, and therefore
74 recommend higher supplemental vitamin D intake, up to 100 µg/d, also for pregnant women (11–13).

75 In general, it is presumed that vitamin D enhances childhood growth, although evidence is limited and
76 conflicting, and in particular the linearity of the relationship is not known (3,14–17). The association
77 between 25(OH)D concentrations and growth might be non-linear and hence dissimilar at different
78 ranges of 25(OH)D, which could explain discrepancies between studies.

79 The effect of vitamin D on childhood growth pattern may best be seen during the prenatal period and
80 infancy due to rapid growth rate. Early growth is particularly relevant for later health outcomes as
81 specific growth patterns have been associated with increased risk of chronic diseases, for example
82 through body composition and metabolic changes. While the associations between prenatal growth

and adult disease are particularly well established (18), growth during the first years after birth is also important (19,20).

Vitamin D intervention in Infants (VIDI) –study is a double-blinded and randomized clinical trial (RCT) comparing the effect of daily vitamin D supplementation of 10 µg or 30 µg from birth until 2 years of age, the primary outcomes being bone strength and infection episodes (21,22). We previously reported an unexpected association between higher maternal and infant 25(OH)D with slower infant growth in the VIDI cohort; mothers with 25(OH)D above 125 nmol/L had the smallest infants at 6 months and 1 year of age (23). In the current study, we aimed to investigate if maternal and child 25(OH)D further predict growth parameters at 2 years of age, and whether the dose of vitamin D supplementation in infancy influences childhood growth pattern from 6 months to 2 years of age.

Materials and Methods

Subjects

In Helsinki, Finland (60th parallel North), we recruited at Kättilöopisto Maternity Hospital 987 families to the VIDI study between January 2013 and June 2014. A description of the recruitment and study protocol has been published previously (21,22). Briefly, according to the inclusion criteria, the mothers were of Northern European origin without regular medication and with singleton pregnancy. Exclusion criteria for the newborns were: nasal continuous positive airway pressure treatment or need for nasogastric tube > one day, intravenous glucose infusion, seizures, and duration of phototherapy > three days. The infants were born between 37 and 42 weeks of gestation with birth weights appropriate for gestational age (standard deviation score [SDS] between -2.0 and +2.0).

Infants were randomized to receive daily vitamin D₃ supplementation with either 10 µg [hereafter referred to as Group-10] or 30 µg [hereafter referred to as Group-30] from age 2 weeks to 2 years. The study included three study visits at the age of 6 months, 1 and 2 years, and retrospectively and prospectively collected questionnaires.

Written informed consent was obtained from the parents at recruitment. This study was conducted according to the guidelines laid down in the Declaration of Helsinki. Ethical approval was obtained from the Research Ethics Committee of the Hospital District of Helsinki and Uusimaa (107/13/03/03/2012). The project protocol is registered at ClinicalTrials.gov (NCT01723852).

Of the recruited 987 families, we excluded 12 who did not meet the inclusion criteria and 1 infant diagnosed with Rieger syndrome, leaving 974 study participants. Further, 126 children were excluded from the present analysis due to lacking data on length and additional 9 due to lacking data on 25(OH)D at 2 years' follow-up. This resulted in a final number of 812 study subjects. Number of subjects varies in some analyses and are presented in tables and figures.

Family data

Parental data were obtained from a self-administered baseline questionnaire, filled out after delivery, and from medical records. Parental heights (cm) and weights (kg) before pregnancy were standardized into sex-specific z-scores. Body mass index (BMI) was calculated (kg/m^2).

Parental education level was categorized into 'lower' and 'higher' education (lower = lower or upper secondary or post-secondary non-tertiary education/less than a bachelor degree, higher = first or second stage of tertiary education/at least a bachelor degree), according to the highest received degree of either parent. Parental smoking status was assessed before pregnancy and at infant age of 2 years and applied as a merged previous and current smoking status. Family income level was enquired with a questionnaire completed at infant age of 2 years.

Child anthropometrics

Birth size was measured by midwives according to standard procedures. The measurements were collected from birth records, and transformed to parity-, gestational age- and sex-specific standard deviation scores (SDS) based on national newborn body size curves (24). Infant weight (kg), length (cm) and head circumference (cm) were measured at 6 months and at 1 and 2 years' follow-up visits by a pediatrician or a research nurse. At 1 and 2 years, mid-upper-arm circumference (MUAC) (mm) was measured. Length was measured with a tabletop meter in a supine position, and weight with an

electronic scale (Seca®, Hamburg, Germany). Weight, length, length-adjusted weight and head circumference were expressed as SDS using age- and sex-specific national references (25) and considered normal when between -2.0 and +2.0 SDS. BMI at 2 years of age was calculated and together with MUAC, standardized into sex-specific z-score within the present study population.

Study compliance and duration of breastfeeding were determined based on prospectively collected study diaries. Average vitamin D intake from food at 1 year of age was calculated based on 3-day food records (26).

Biochemical analyses

We analyzed 25(OH)D concentration from maternal serum samples in early pregnancy, at birth from umbilical cord blood (UCB), and from infant serum samples at the age of 1 and 2 years using the IDS-iSYS fully automated immunoassay system with chemiluminescence detection (Immunodiagnostic Systems Ltd., Bolton, UK). Pregnancy samples were collected at prenatal clinics on average at gestational week 11 between June 2012 and February 2014 as part of the mothers' normal follow-up [hereafter referred to as Pregnancy 25(OH)D] (23). UCB for 25(OH)D measurement was obtained at birth (gestational weeks 37 to 42) between January 2013 and June 2014 [hereafter referred to as UCB 25(OH)D]. Maternal 25(OH)D refers to both Pregnancy and UCB 25(OH)D. Children's samples at 1 year follow-up were obtained between December 2013 and May 2015 [hereafter referred to as Infant 25(OH)D], and samples at 2 years follow-up between December 2014 and May 2016 [hereafter referred to as Toddler 25(OH)D].

Pregnancy serum and UCB plasma 25(OH)D were analyzed simultaneously and Infant and Toddler serum 25(OH)D in a separate series with intra-assay variation <7% for Pregnancy 25(OH)D and Infant/Toddler 25(OH)D, and <13% for UCB 25(OH)D. The quality and accuracy of the 25(OH)D analyses are validated on an ongoing basis by participation in the vitamin D External Quality Assessment Scheme (DEQAS, Charing Cross Hospital, London, UK). The method showed a $\leq 8\%$ positive bias against NIST Reference Measurement Procedure. Detailed information on the 25(OH)D analysis has been previously reported (22).

Vitamin D sufficiency was defined as $25(\text{OH})\text{D} \geq 50 \text{ nmol/L}$ (5,6) . Further, we used additional cut-off values for $25(\text{OH})\text{D}$, namely 75 nmol/L , which has been suggested to be a higher threshold value for bone health (11) , and 125 nmol/L , above which values have been related to health risks (5,6).

Statistical analyses

The normality of the variables was visually inspected, and statistical tests were chosen accordingly. Infant and family characteristics were reported as means, standard deviations, and percentages. Covariates were chosen based on literature and consistent association with several growth measures. Missing values of covariates were multiple imputed (5 imputations). The difference between intervention groups was examined with Independent-Samples T-test, Mann-Whitney U-test or Pearson Chi-Square test.

Growth rate, referred to here as conditional growth, was investigated by using the residuals from linear regression models in which body size SDS at each successive age was regressed on corresponding body size SDS at all earlier ages (27). These residuals indicate how much a measurement of body size at each time point differs from that predicted by the corresponding measurements at earlier time points.

We used univariate and multivariate linear and quadratic regression analysis to determine associations between $25(\text{OH})\text{D}$ and growth measures. We show in the tables unadjusted model 1, and model 2 adjusted with corresponding birth size, maternal and paternal height z-scores and intervention group. All analyses were also stratified by intervention group and shown in relevant tables separately. Additional adjustments were conducted with covariates of maternal prepregnancy BMI and paternal BMI, parental smoking status, parental education level, family income level, and duration of breastfeeding. These results are reported in the text only if an effect was observed.

Further, we investigated child growth in categories of $25(\text{OH})\text{D}$ with ANCOVA adjusted for corresponding birth size SDS, maternal and paternal height z-scores and intervention group. Maternal $25(\text{OH})\text{D}$ concentrations were categorized into four groups; $<50 \text{ nmol/L}$, $50\text{-}74.9 \text{ nmol/L}$ (reference

group), 75-125 nmol/L and >125 nmol/L, and Toddler 25(OH)D into three groups; <75 nmol/L (reference group), 75-125 nmol/L and >125 nmol/L due to only five toddlers having a concentration below 50 nmol/L. In addition, Toddler 25(OH)D concentration was categorized into quartiles; <81.2 nmol/L (reference group), 81.2-99.2 nmol/L, 99.3-120.7 nmol/L and >121 nmol/L. Differences in child size between categories were compared with linear regression applying 50-74.9 nmol/L, <75 nmol/L or first quartile as a reference group. Additional adjustments were conducted with covariates of maternal prepregnancy BMI and paternal BMI, parental smoking status, parental education level, family income level, and duration of breastfeeding. These results are reported in the text only if an effect on the results was observed.

Statistical significance was determined at $P < 0.05$. All statistical analyses were conducted using the IBM SPSS program for Windows, version 25 (IBM, Chicago, IL, USA).

Results

Subject characteristics are shown in Tables 1 and 2 according to intervention groups. Infant 25(OH)D concentrations were higher at the age of 1 and 2 years in Group-30 compared with Group-10 but no difference was observed in mean values of body size parameters (22). However, when we compared mean conditional growth values indicating growth rate, we discovered that growth in length and head circumference were slower between 6 months and 1 year, but growth in weight and length-adjusted weight were accelerated between 1 and 2 years in Group-30 compared with Group-10 (Figures 1 and 2). Almost all subjects (>92%) had normal body size (measured values between -2.0 and +2.0 SDS) at all time points.

At 1 year, total ($r=0.56$, $p<0.001$) and supplemental vitamin D intake ($r=0.59$, $p<0.001$) correlated with Infant 25(OH)D. Similarly, supplemental vitamin D intake at 2 years correlated with Toddler 25(OH)D ($r=0.61$, $p<0.001$). To exclude the possibility that body size as such, by possible dilution or fat mass, affected how vitamin D intake was reflected in 25(OH)D concentration, we tested

interactions between supplemental vitamin D intake (compliance-based $\mu\text{g/day}$) and weight (kg) in all linear models, and no interaction was detected.

No linear relation existed between Maternal 25(OH)D and offspring body size at 2 years (Table 3).

But the mothers whose Pregnancy 25(OH)D was above 125 nmol/L had lighter (measured in weight) and thinner (measured in length-adjusted weight, MUAC and BMI) children at 2 years of age compared with the reference group of children with Pregnancy 25(OH)D 50-74.9 nmol/L (Figure 3).

A quadratic association was confirmed between Pregnancy 25(OH)D and the children's length-adjusted weight and BMI at 2 years ($p<0.003$) suggesting an inverse U-shaped association (Figure 3).

Toddlers at 2 years of age with UCB 25(OH)D below 50 nmol/L at birth were taller than the reference group of 50-74.9 nmol/L (Figure 4) but this association was attenuated after adjustment for maternal prepregnancy BMI, paternal BMI, parental smoking status, parental education level, family income level, and duration of breastfeeding ($p=0.062$). Toddlers with UCB 25(OH)D above 125 nmol/L were thinner (in BMI) at 2 years compared with the reference group of 50-74.9 nmol/L (Figure 4). Higher Pregnancy 25(OH)D and UCB 25(OH)D associated with accelerated growth in head circumference at 2 years, while no association for other growth parameters was observed (Table 4).

We have previously reported that across the VIDI cohort, higher Infant 25(OH)D at 1 year associated with slower growth at 1 year in several growth parameters (23). In the present study, we stratified the results according to intervention group, and observed that linear associations between Infant 25(OH)D and growth measures disappeared in Group-10 but were enhanced in Group-30 (Table 5).

At 2 years in the whole cohort, higher Toddler 25(OH)D associated linearly with smaller body size in all other parameters except head circumference (Table 6). The association between Toddler 25(OH)D and length attenuated after full adjustment for maternal and paternal factors ($p=0.054$). After stratification these linear results at 2 years of age by intervention group, associations between Toddler 25(OH)D and growth measures attenuated for length and remained for weight, length-adjusted weight and BMI in both groups, while for MUAC the association disappeared in Group-10 and remained in Group-30 (Table 6).

In the whole cohort, a quadratic association was observed between Toddler 25(OH)D and head circumference ($p < 0.035$) implying an inverse U-shaped association (Figure 5). Toddler 25(OH)D had no linear relation for conditional growth at 2 years (Table 4).

When comparing growth parameters in three groups of Toddler 25(OH)D, those with 25(OH)D above 125 nmol/L (highest group) were lighter (in weight) and thinner (in length-adjusted weight and BMI) compared with the reference group with 25(OH)D < 75 nmol/L (Figure 5). Toddlers with 25(OH)D between 75 nmol/L and 125 nmol/L had larger head circumference than the reference group of < 75 nmol/L (Figure 5). Figure 6 shows adjusted mean values for growth measures in quartiles of Toddler 25(OH)D. Children in the highest quartile of 25(OH)D (> 121 nmol/L) were shorter (in length), lighter (in weight) and thinner (in length-adjusted weight and BMI) than the reference group in the lowest quartile (< 81.2 nmol/L) (Figure 6).

Discussion

We examined the association of vitamin D in pregnancy and in early childhood with child growth in an RCT-based cohort in Northern Europe with low sunlight exposure. VIDI study is an intervention trial with >800 infants comparing the effect of vitamin D supplementation of 10 µg/d and 30 µg/d during the first 2 years of life.

The dose of vitamin D supplementation had little effect on early childhood growth, as the mean body size measures were similar in both intervention groups (22). However, growth in length and head circumference was slower between 6 months and 1 year but growth in weight and length-adjusted weight was more rapid between 1 and 2 years in Group-30 compared with Group-10. Almost all children were vitamin D sufficient (≥ 50 nmol/L) and 21% of the children had 25(OH)D above 125 nmol/L at 2 years. The possible effect of vitamin D on growth may be mediated through 25(OH)D concentration, as we observed that higher 25(OH)D in early pregnancy, at birth, and at 1 and 2 years of age associated with smaller body size in the offspring during 2 years' follow-up.

Previous studies on vitamin D and growth in early childhood have been inconclusive (15,16,28–30).

We have previously reported an inverse association between both Maternal 25(OH)D and Infant 25(OH)D and growth measures at age 6 months and 1 year (23). These findings were obtained before the intervention code was opened and were based solely on measured 25(OH)D concentration. In line with a Danish study (28) and contrary to an Equadorian study (30), we now observed that higher Toddler 25(OH)D at age 2 years associated with smaller anthropometric growth parameters.

However, at 1 year, the associations were not observed within Group-10 but were enhanced in Group-30. This is consistent with a non-linear relationship, implying that the effect of vitamin D dosage on growth would depend on the attained 25(OH)D. At 2 years, these inverse associations between 25(OH)D and most growth measures remained in both intervention groups. This might be explained by differing growth rates between intervention groups and time points. The intervention effect may be smaller at 2 years than at 1 year because other factors such as food intake, physical activity and

endocrine factors, especially growth hormone secretion, have a larger role in child growth after infancy.

We also applied both clinical cut-off values and quartiles for Toddler 25(OH)D at 2 years. These results demonstrated that toddlers with 25(OH)D above 125 nmol/L or 121 nmol/L were the shortest (in length), lightest (in weight) and thinnest (in length-adjusted weight and BMI) at 2 years of age. In addition to our previous findings (31,32), others have found unfavorable and non-linear relations between vitamin D and child health outcomes (33,34).

In longitudinal analysis, maternal 25(OH)D concentration in early pregnancy and at birth had no linear relation to offspring growth anthropometry at 2 years. However, mothers with 25(OH)D above 125 nmol/L in early pregnancy, had the lightest and thinnest children at age 2 years, suggesting that maternal 25(OH)D may affect infant growth until age 1 year but the effect diminishes thereafter, possibly due to catch-up growth (23,35,36). Furthermore, other factors at an older age possibly have a larger role than maternal 25(OH)D if it is in the “moderate range”. In line with our findings, Christensen et al. found an inverse relation between UCB 25(OH)D and offspring leg length from age 1.5 to 3 years of age (37). Further, U- or J-shaped association have been suggested to exist between maternal 25(OH)D and prenatal growth (38,39). However, several studies have found no relation between maternal 25(OH)D and offspring postnatal growth (40–45).

Conflicting results between studies may be related to geographical and genetic differences, leading to e.g. variable response to vitamin D supplementation (46,47), and varying cut-offs applied for 25(OH)D. Furthermore, it may be that only severe vitamin D deficiency (<30 nmol/L) (36,48), and, as suggested by our results, high 25(OH)D (>125 nmol/L) impair childhood growth. Vitamin D supplementation without vitamin D deficiency and “moderate” 25(OH)D concentrations would therefore not show associations with growth parameters. In our study, both maternal and child’s 25(OH)D concentrations were at exceptionally high level compared with many other study cohorts. This was due to widely used vitamin D supplementation during pregnancy and national vitamin D food fortification (49,50). In the VIDI cohort we have shown that genotype modifies individual’s 25(OH)D and the response to vitamin D supplementation (47,51). This individual dose-response was

shown in Group-30 but not in Group-10 (47), which might explain why we in the current study did not observe a similar relation between both vitamin D supplementation and vitamin D concentration and growth.

Severe vitamin D deficiency leads to growth impairment. If vitamin D indeed has an inverse U-shaped association with early growth, the mechanism how high 25(OH)D could disturb normal growth is unclear. Its role as a plasma calcium regulator could be one possible pathway. If high 25(OH)D leads to high circulating 1,25-dihydroxyvitamin D [1,25(OH)₂D], this enhances calcium and phosphate resorption from bone to increase plasma calcium levels, thus possibly impairing growth (52). Based on one study, maternal 25(OH)D would not increase 1,25(OH)₂D after 25(OH)D reaches the level of 100 nmol/L (53). However, many organs and tissues, like the growth plate, have the ability to produce 1,25(OH)₂D locally (54,55) and thus high 25(OH)D could lead to high local production of 1,25(OH)₂D. In our cohort, at age 1 year, Infant 25(OH)D correlated with plasma calcium (56) and PTH concentrations (23). Furthermore, PTH levels were lower in Group-30 than Group-10 at age 1 year and 2 years. These observations suggest that vitamin D influenced the endocrine system. However, the intervention group did not affect measured bone parameters (22). Vitamin D may also affect growth-regulating hormones, e.g. insulin-like growth factor 1 (IGF-1) which may activate 1,25(OH)₂D production (57, 58) .

We have a large and homogenous sample of North-European subjects with longitudinal data from early pregnancy until child age of 2 years covering all seasons. Data were collected and processed in a standardized fashion in a single maternity hospital. However, subjects had more commonly a higher education and normal weight than nationally representative population. The small number of subjects having maternal 25(OH)D values in both extreme ends, and only few vitamin D insufficient children may have constrained our analyses. We applied multiple methods to discover the possible relation between vitamin D and childhood growth and adjusted for potential confounders. As we did not observe a direct effect of vitamin D supplementation but rather consistent associations between 25(OH)D and growth parameters, we cannot determine true direction of causality. However, interactions of absolute body size and vitamin D intake were not observed.

The debate about the optimal 25(OH)D level for health outcomes is still ongoing (59,60). Studies with subjects of high 25(OH)D concentrations are scarce (61), especially in geographical locations with limited solar radiation, hence our data with exceptionally high 25(OH)D values are of importance in gaining more understanding about the relationship between vitamin D and health.

Conclusion

In this large study, high maternal and child 25(OH)D concentrations were associated with delayed growth in 1- and 2-years old children, but infant vitamin D supplementation in itself had only a minor impact on growth measures. Our results imply that vitamin D may have an inverse U-shaped relation with childhood growth. Therefore, aiming for higher than sufficient 25(OH)D levels with high vitamin D dosages may have undesired consequences on child growth. The clinical relevance of our results, however, remains to be evaluated in future studies.

Acknowledgements

We acknowledge the important work of our research nurses Sirpa Nolvi, Rhea Paajanen, Nea Boman and Päivi Turunen, and laboratory technician Sari Lindén in data collection and analysis. We thank the midwives and laboratory technicians at Kätilöopisto Maternity Hospital for obtaining umbilical cord blood samples, and biostatistician Paula Bergman for her advice on statistical procedures (University of Helsinki and Helsinki University Hospital). Foremost, we thank all the families that participated in this study.

Data Availability

Some or all datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

- 355 1. Munns CF, Shaw N, Kiely M, Specker BL, Thacher TD, Ozono K, Michigami T, Tiosano D,
356 Mughal MZ, Mäkitie O, Ramos-Abad L, Ward L, DiMeglio LA, Atapattu N, Cassinelli H,
357 Braegger C, Pettifor JM, Seth A, Idris HW, Bhatia V, Fu J, Goldberg G, Säwendahl L, Khadgawat
358 R, Pludowski P, Maddock J, Hyppönen E, Oduwole A, Frew E, Aguiar M, Tulchinsky T, Butler
359 G, Högl W. Global Consensus Recommendations on Prevention and Management of
360 Nutritional Rickets. *The Journal of Clinical Endocrinology & Metabolism* 2016;101(2):394–415.
- 361 2. Amraei M, Mohamadpour S, Sayehmiri K, Mousavi SF, Shirzadpour E, Moayeri A. Effects of
362 Vitamin D Deficiency on Incidence Risk of Gestational Diabetes Mellitus: A Systematic Review
363 and Meta-analysis. *Front. Endocrinol.* 2018;9:7.
- 364 3. Bi WG, Nuyt AM, Weiler H, Leduc L, Santamaria C, Wei SQ. Association Between Vitamin D
365 Supplementation During Pregnancy and Offspring Growth, Morbidity, and Mortality: A
366 Systematic Review and Meta-analysis. *JAMA Pediatr.* 2018;172(7):635–645.
- 367 4. Tous M, Villalobos M, Iglesias L, Fernández-Barrés S, Arijá V. Vitamin D status during
368 pregnancy and offspring outcomes: a systematic review and meta-analysis of observational
369 studies. *Eur J Clin Nutr* 2020;74(1):36–53.
- 370 5. Lips P, Cashman KD, Lamberg-Allardt C, Bischoff-Ferrari HA, Obermayer-Pietsch BR, Bianchi
371 M, Stepan J, El-Hajj Fuleihan G, Bouillon R. MANAGEMENT OF ENDOCRINE DISEASE:
372 Current vitamin D status in European and Middle East countries and strategies to prevent vitamin
373 D deficiency; a position statement of the European Calcified Tissue Society. *Eur.J.Endocrinol.*
374 2019;(Journal Article). doi:10.1530/EJE-18-0736.
- 375 6. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA,
376 Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA. The 2011
377 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine:
378 What Clinicians Need to Know. *The Journal of Clinical Endocrinology & Metabolism*
379 2011;96(1):53–58.
- 380 7. Cashman KD, Sheehy T, O'Neill CM. Is vitamin D deficiency a public health concern for low
381 middle income countries? A systematic literature review. *Eur J Nutr* 2019;58(1):433–453.
- 382 8. Saraf R, Morton SMB, Camargo CA, Grant CC. Global summary of maternal and newborn
383 vitamin D status - a systematic review: Global maternal and newborn vitamin D status. *Maternal*
384 *& Child Nutrition* 2016;12(4):647–668.
- 385 9. *Syödään yhdessä - ruokasuositukset lapsiperheille*. THL; 2019. Available at:
386 <http://www.julkari.fi/handle/10024/137459>. Accessed August 10, 2020.
- 387 10. The WHO Reproductive Health Library. WHO recommendation regarding Vitamin D
388 supplementation during pregnancy. 2016. Available at:
389 [https://extranet.who.int/rhl/topics/preconception-pregnancy-childbirth-and-postpartum-](https://extranet.who.int/rhl/topics/preconception-pregnancy-childbirth-and-postpartum-care/antenatal-care/who-recommendation-regarding-vitamin-d-supplementation-during-pregnancy)
390 [care/antenatal-care/who-recommendation-regarding-vitamin-d-supplementation-during-](https://extranet.who.int/rhl/topics/preconception-pregnancy-childbirth-and-postpartum-care/antenatal-care/who-recommendation-regarding-vitamin-d-supplementation-during-pregnancy)
391 [pregnancy](https://extranet.who.int/rhl/topics/preconception-pregnancy-childbirth-and-postpartum-care/antenatal-care/who-recommendation-regarding-vitamin-d-supplementation-during-pregnancy).
- 392 11. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH,
393 Weaver CM, Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency:
394 an Endocrine Society clinical practice guideline. *J.Clin.Endocrinol.Metab.* 2011;96(7):1911–
395 1930.
- 396 12. Wagner CL, Hollis BW. The Implications of Vitamin D Status During Pregnancy on Mother and
397 her Developing Child. *Front. Endocrinol.* 2018;9:500.

- 398 13. Pérez-López FR, Pilz S, Chedraui P. Vitamin D supplementation during pregnancy: an overview.
399 *Curr. Opin. Obstet. Gynecol.* 2020. doi:10.1097/GCO.0000000000000641.
- 400 14. Santamaria C, Bi WG, Leduc L, Tabatabaei N, Jantchou P, Luo Z-C, Audibert F, Nuyt AM, Wei
401 SQ. Prenatal vitamin D status and offspring's growth, adiposity and metabolic health: a
402 systematic review and meta-analysis. *Br J Nutr* 2018;119(3):310–319.
- 403 15. Trilok-Kumar G, Kaur M, Rehman AM, Arora H, Rajput MM, Chugh R, Kurpad A, Sachdev HS,
404 Filteau S. Effects of vitamin D supplementation in infancy on growth, bone parameters, body
405 composition and gross motor development at age 3–6 years: follow-up of a randomized
406 controlled trial. *Int. J. Epidemiol.* 2015;44(3):894–905.
- 407 16. Gallo S, Hazell T, Vanstone CA, Agellon S, Jones G, L'Abbe M, Rodd C, Weiler HA. Vitamin D
408 supplementation in breastfed infants from Montreal, Canada: 25-hydroxyvitamin D and bone
409 health effects from a follow-up study at 3 years of age. *Osteoporos.Int.* 2016;(Journal Article).
410 doi:10.1007/s00198-016-3549-z.
- 411 17. Roth DE, Morris SK, Zlotkin S, Gernand AD, Ahmed T, Shanta SS, Papp E, Korsiak J, Shi J,
412 Islam MM, Jahan I, Keya FK, Willan AR, Weksberg R, Mohsin M, Rahman QS, Shah PS,
413 Murphy KE, Stimec J, Pell LG, Qamar H, Al Mahmud A. Vitamin D Supplementation in
414 Pregnancy and Lactation and Infant Growth. *N. Engl. J. Med.* 2018;379(6):535–546.
- 415 18. Knop MR, Geng TT, Gorny AW, Ding R, Li C, Ley SH, Huang T. Birth Weight and Risk of
416 Type 2 Diabetes Mellitus, Cardiovascular Disease, and Hypertension in Adults: A Meta-Analysis
417 of 7 646 267 Participants From 135 Studies. *J.Am.Heart Assoc.* 2018;7(23):e008870.
- 418 19. Eriksson JG, Forsen TJ, Osmond C, Barker DJ. Pathways of infant and childhood growth that
419 lead to type 2 diabetes. *Diabetes Care* 2003;26(11):3006–3010.
- 420 20. Lahti M, Rääkkönen K, Wahlbeck K, Heinonen K, Forsén T, Kajantie E, Pesonen A-K, Osmond
421 C, Barker DJP, Eriksson JG. Growth in Infancy and Childhood and Hospitalization for
422 Personality Disorders in Adulthood: The Helsinki Birth Cohort Study. *Journal of Personality*
423 *Disorders* 2011;25(5):620–633.
- 424 21. Helve O, Viljakainen H, Holmlund-Suila E, Rosendahl J, Hauta-alus H, Enlund-Cerullo M,
425 Valkama S, Heinonen K, Raikkonen K, Hytinantti T, Mäkitie O, Andersson S. Towards
426 evidence-based vitamin D supplementation in infants: vitamin D intervention in infants (VIDI) -
427 study design and methods of a randomised controlled double-blinded intervention study. *BMC*
428 *Pediatr.* 2017;17(1):91-017-0845–5.
- 429 22. Rosendahl J, Valkama S, Holmlund-Suila E, Enlund-Cerullo M, Hauta-alus H, Helve O,
430 Hytinantti T, Levälahti E, Kajantie E, Viljakainen H, Mäkitie O, Andersson S. Effect of Higher
431 vs Standard Dosage of Vitamin D3 Supplementation on Bone Strength and Infection in Healthy
432 Infants: A Randomized Clinical Trial. *JAMA Pediatr* 2018;172(7):646–654.
- 433 23. Hauta-alus HH, Kajantie E, Holmlund-Suila EM, Rosendahl J, Valkama SM, Enlund-Cerullo M,
434 Helve OM, Hytinantti TK, Viljakainen H, Andersson S, Mäkitie O. High Pregnancy, Cord Blood,
435 and Infant Vitamin D Concentrations May Predict Slower Infant Growth. *J. Clin. Endocrinol.*
436 *Metab.* 2019;104(2):397–407.
- 437 24. Sankilampi U, Hannila M-L, Saari A, Gissler M, Dunkel L. New population-based references for
438 birth weight, length, and head circumference in singletons and twins from 23 to 43 gestation
439 weeks. *Ann. Med.* 2013;45(5–6):446–454.

- 440 25. Saari A, Sankilampi U, Hannila M-L, Kiviniemi V, Kesseli K, Dunkel L. New Finnish growth
441 references for children and adolescents aged 0 to 20 years: Length/height-for-age, weight-for-
442 length/height, and body mass index-for-age. *Annals of Medicine* 2011;43(3):235–248.
- 443 26. Hauta-alus HH, Korkalo L, Holmlund-Suila EM, Rosendahl J, Valkama SM, Enlund-Cerullo M,
444 Helve OM, Hytinantti TK, Makitie OM, Andersson S, Viljakainen HT. Food and Nutrient Intake
445 and Nutrient Sources in 1-Year-Old Infants in Finland: A Cross-Sectional Analysis. *Nutrients*
446 2017;9(12):10.3390/nu9121309.
- 447 27. De Stavola BL, Nitsch D, dos Santos Silva I, McCormack V, Hardy R, Mann V, Cole TJ, Morton
448 S, Leon DA. Statistical issues in life course epidemiology. *Am.J.Epidemiol.* 2006;163(1):84–96.
- 449 28. Arnberg K, Østergård M, Madsen A, Krarup H, Michaelsen K, Mølgaard C. Associations
450 between vitamin D status in infants and blood lipids, body mass index and waist circumference:
451 Vitamin D, lipids, BMI and waist circumference in infants. *Acta Paediatrica* 2011;100(9):1244–
452 1248.
- 453 29. Holmlund-Suila E, Viljakainen H, Hytinantti T, Lamberg-Allardt C, Andersson S, Mäkitie O.
454 High-dose vitamin d intervention in infants--effects on vitamin d status, calcium homeostasis, and
455 bone strength. *J.Clin.Endocrinol.Metab.* 2012;97(11):4139–4147.
- 456 30. Mokhtar RR, Holick MF, Sempértegui F, Griffiths JK, Estrella B, Moore LL, Fox MP, Hamer
457 DH. Vitamin D status is associated with underweight and stunting in children aged 6-36 months
458 residing in the Ecuadorian Andes. *Public Health Nutr* 2018;21(11):1974–1985.
- 459 31. Rosendahl J, Holmlund-Suila E, Helve O, Viljakainen H, Hauta-alus H, Valkama S, Enlund-
460 Cerullo M, Hytinantti T, Tervahartiala T, Sorsa T, Mäkitie O, Andersson S. 25-hydroxyvitamin D
461 correlates with inflammatory markers in cord blood of healthy newborns. *Pediatr Res*
462 2017;81(5):731–735.
- 463 32. Rosendahl J, Pelkonen AS, Helve O, Hauta-alus H, Holmlund-Suila E, Valkama S, Enlund-
464 Cerullo M, Viljakainen H, Hytinantti T, Mäkitie O, Andersson S, Mäkelä MJ. High-Dose
465 Vitamin D Supplementation Does Not Prevent Allergic Sensitization of Infants. *J. Pediatr.*
466 2019;209:139-145.e1.
- 467 33. Zhu P, Tong SL, Hao JH, Tao RX, Huang K, Hu WB, Zhou QF, Jiang XM, Tao FB. Cord blood
468 vitamin D and neurocognitive development are nonlinearly related in toddlers. *J.Nutr.*
469 2015;145(6):1232–1238.
- 470 34. Nwaru BI, Hadkhale K, Hämäläinen N, Takkinen H-M, Ahonen S, Ilonen J, Toppari J, Niemelä
471 O, Haapala A-M, Veijola R, Knip M, Virtanen SM. Vitamin D intake during the first 4 years and
472 onset of asthma by age 5: A nested case-control study. *Pediatr Allergy Immunol* 2017;28(7):641–
473 648.
- 474 35. Leffelaar ER, Vrijkotte TG, van Eijnden M. Maternal early pregnancy vitamin D status in relation
475 to fetal and neonatal growth: results of the multi-ethnic Amsterdam Born Children and their
476 Development cohort. *Br.J.Nutr.* 2010;104(1):108–117.
- 477 36. Eckhardt CL, Gernand AD, Roth DE, Bodnar LM. Maternal vitamin D status and infant
478 anthropometry in a US multi-centre cohort study. *Ann.Hum.Biol.* 2015;42(3):215–222.
- 479 37. Christensen ME, Beck-Nielsen SS, Dalgard C, Larsen SD, Lykkedegn S, Kyhl HB, Husby S,
480 Christesen HT. A novel inverse association between cord 25-hydroxyvitamin D and leg length in
481 boys up to three years. An Odense Child Cohort study. *PLoS One* 2018;13(6):e0198724.

482 38. Bodnar LM, Catov JM, Zmuda JM, Cooper ME, Parrott MS, Roberts JM, Marazita ML, Simhan
483 HN. Maternal serum 25-hydroxyvitamin D concentrations are associated with small-for-
484 gestational age births in white women. *J.Nutr.* 2010;140(5):999–1006.

485 39. Zhu P, Tong SL, Hu WB, Hao JH, Tao RX, Huang K, Mou Z, Zhou QF, Jiang XM, Tao FB. Cord
486 Blood 25-hydroxyvitamin D and Fetal Growth in the China-Anhui Birth Cohort Study. *Sci.Rep.*
487 2015;5(Journal Article):14930.

488 40. Sauder K, Koeppen H, Shapiro A, Kalata K, Stamatoiu A, Ringham B, Glueck D, Norris J,
489 Dabelea D. Prenatal Vitamin D Intake, Cord Blood 25-Hydroxyvitamin D, and Offspring Body
490 Composition: The Healthy Start Study. *Nutrients* 2017;9(7):790.

491 41. Gale CR, Robinson SM, Harvey NC, Javaid MK, Jiang B, Martyn CN, Godfrey KM, Cooper C,
492 Princess Anne Hospital Study Group. Maternal vitamin D status during pregnancy and child
493 outcomes. *Eur.J.Clin.Nutr.* 2008;62(1):68–77.

494 42. Egge S, Christensen N, Lykkedegn S, Jensen TK, Christesen HT. Cord serum 25-hydroxyvitamin
495 D is not associated with cranial anthropometrics in infants up to 6 months of age. An Odense
496 Child Cohort study. *J.Bone Miner.Metab.* 2017;(Journal Article). doi:10.1007/s00774-017-0881-
497 0.

498 43. Vieth Strey S, Kristine Moller U, Rejnmark L, Heickendorff L, Mosekilde L, Vestergaard P.
499 Maternal and infant vitamin D status during the first 9 months of infant life-a cohort study.
500 *Eur.J.Clin.Nutr.* 2013;67(10):1022–1028.

501 44. Larsen SD, Christensen ME, Dalgard C, Lykkedegn S, Andersen LB, Andersen MS, Glintborg D,
502 Christesen HT. Pregnancy or cord 25-hydroxyvitamin D is not associated with measures of body
503 fat or adiposity in children from three months to three years of age. An Odense Child Cohort
504 study. *Clin.Nutr.* 2019;(Journal Article).

505 45. Gould JF, Anderson AJ, Yelland LN, Smithers LG, Skeaff CM, Zhou SJ, Gibson RA, Makrides
506 M. Association of cord blood vitamin D with early childhood growth and neurodevelopment.
507 *J.Paediatr.Child Health* 2017;53(1):75–83.

508 46. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, Tamez H, Zhang D, Bhan I,
509 Karumanchi SA, Powe NR, Thadhani R. Vitamin D-binding protein and vitamin D status of black
510 Americans and white Americans. *N. Engl. J. Med.* 2013;369(21):1991–2000.

511 47. Enlund-Cerullo M, Koljonen L, Holmlund-Suila E, Hauta-alus H, Rosendahl J, Valkama S, Helve
512 O, Hytinantti T, Viljakainen H, Andersson S, Mäkitie O, Pekkinen M. Genetic Variation of the
513 Vitamin D Binding Protein Affects Vitamin D Status and Response to Supplementation in
514 Infants. *J. Clin. Endocrinol. Metab.* 2019;104(11):5483–5498.

515 48. Ong YL, Quah PL, Tint MT, Aris IM, Chen LW, van Dam RM, Heppe D, Saw SM, Godfrey
516 KM, Gluckman PD, Chong YS, Yap F, Lee YS, Foong-Fong Chong M. The association of
517 maternal vitamin D status with infant birth outcomes, postnatal growth and adiposity in the first 2
518 years of life in a multi-ethnic Asian population: the Growing Up in Singapore Towards healthy
519 Outcomes (GUSTO) cohort study. *Br.J.Nutr.* 2016;(Journal Article):1–11.

520 49. Hauta-alus HH, Holmlund-Suila EM, Rita HJ, Enlund-Cerullo M, Rosendahl J, Valkama SM,
521 Helve OM, Hytinantti TK, Surcel HM, Makitie OM, Andersson S, Viljakainen HT. Season,
522 dietary factors, and physical activity modify 25-hydroxyvitamin D concentration during
523 pregnancy. *Eur.J.Nutr.* 2017;DOI 10.1007/s00394-017-1417-z(Journal Article).
524 doi:10.1007/s00394-017-1417-z.

50. Jääskeläinen T, Itkonen ST, Lundqvist A, Erkkola M, Koskela T, Lakkala K, Dowling KG, Hull GL, Kroger H, Karppinen J, Kyllönen E, Harkanen T, Cashman KD, Männistö S, Lamberg-Allardt C. The positive impact of general vitamin D food fortification policy on vitamin D status in a representative adult Finnish population: evidence from an 11-y follow-up based on standardized 25-hydroxyvitamin D data. *Am.J.Clin.Nutr.* 2017;105(6):1512–1520.
51. Kämpe A, Enlund-Cerullo M, Valkama S, Holmlund-Suila E, Rosendahl J, Hauta-alus H, Pekkinen M, Andersson S, Mäkitie O. Genetic variation in GC and CYP2R1 affects 25-hydroxyvitamin D concentration and skeletal parameters: A genome-wide association study in 24-month-old Finnish children. *PLoS Genet.* 2019;15(12):e1008530.
52. Goltzman D. Functions of vitamin D in bone. *Histochem.Cell Biol.* 2018;149(4):305–312.
53. Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. *J.Bone Miner.Res.* 2011;26(10):2341–2357.
54. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. *Am.J.Clin.Nutr.* 2008;88(2):491S-499S.
55. St-Arnaud R. The direct role of vitamin D on bone homeostasis. *Arch. Biochem. Biophys.* 2008;473(2):225–230.
56. Valkama S, Holmlund-Suila E, Enlund-Cerullo M, Rosendahl J, Hauta-alus H, Helve O, Hytinantti T, Viljakainen H, Andersson S, Makitie O. No Severe Hypercalcemia with Daily Vitamin D3 Supplementation of up to 30 microg during the First Year of Life. *Horm.Res.Paediatr.* 2017;88(2):147–154.
57. Mortensen C, Mølgaard C, Hauger H, Kristensen M, Damsgaard CT. Winter vitamin D3 supplementation does not increase muscle strength, but modulates the IGF-axis in young children. *Eur J Nutr* 2019;58(3):1183–1192.
58. Esposito S, Leonardi A, Lanciotti L, Cofini M, Muzi G, Penta L. Vitamin D and growth hormone in children: a review of the current scientific knowledge. *J Transl Med* 2019;17(1):87.
59. Cashman KD, Kiely M. Nutrition: new guidelines on vitamin D-ficiency--clear or confusing? *Nat.Rev.Endocrinol.* 2011;7(10):566–568.
60. Kiely ME, Wagner CL, Roth DE. Vitamin D in pregnancy: Where we are and where we should go. *The Journal of Steroid Biochemistry and Molecular Biology* 2020;201:105669.
61. Durazo-Arvizu RA, Dawson-Hughes B, Kramer H, Cao G, Merkel J, Coates PM, Sempos CT. The Reverse J-Shaped Association Between Serum Total 25-Hydroxyvitamin D Concentration and All-Cause Mortality: The Impact of Assay Standardization. *Am. J. Epidemiol.* 2017;185(8):720–726.

Figure 1 Mean (95% CI) values of conditional growth at 1 year of age, i.e. growth rate, according to intervention groups. Conditional growth at 1 year refers to the difference of body size at 1 year with expected based on body size at birth and 6 months, expressed in standardized residuals, SD units. Statistical difference tested with Independent-Samples T test. Number of subjects for length and length-adjusted weight: 10 µg, n=401; 30 µg, n=410, for weight: 10 µg, n=402; 30 µg, n=410, and for head circumference: 10 µg, n=387; 30 µg, n=394.

Figure 2 Mean (95% CI) values of conditional growth at 2 years of age, i.e. growth rate, according to intervention groups. Conditional growth at 2 years refers to the difference of body size at 2 years with expected based on body size at birth, 6 months and 1 year, expressed in standardized residuals, SD units. Statistical difference tested with Independent-Samples T test. Number of subjects for length: 10 µg, n=401; 30 µg, n=410, for weight: 10 µg, n=401; 30 µg, n=409, for length-adjusted weight: 10 µg, n=400; 30 µg, n=409, and for head circumference: 10 µg, n=380; 30 µg, n=387.

Figure 3 Pregnancy 25(OH)D and offspring growth measures at 2 years of age. Symbols present adjusted mean (95% CI) values of growth measures in Pregnancy 25(OH)D categories of <50 nmol/L (n=24), 50-74.9 nmol/L (n=220) (reference group), 75-125 nmol/L (n=420) and >125 nmol/L (n=16). Adjustments are for corresponding birth size SDS, maternal and paternal height z-scores and intervention group. Statistical difference tested with linear regression with 50-74.9 nmol/L applied as a reference group. 25(OH)D, 25-hydroxy vitamin D; SDS, SD-score, based on Finnish sex- and age-specific normative data for infant growth; Length/weight, length-adjusted weight, HC, head circumference; MUAC, mid-upper-arm circumference (in z-score); BMI, body mass index (in z-score). The reference group's symbol has been highlighted.

Figure 4 Umbilical cord blood (UCB) 25(OH)D and offspring growth measures at 2 years of age. Symbols present adjusted mean (95% CI) values of growth measures in UCB 25(OH)D categories of <50 nmol/L (n=27), 50-74.9 nmol/L (n=304) (reference group), 75-125 nmol/L (n=429) and >125 nmol/L (n=34). Adjustments are for corresponding birth size SDS, maternal and paternal height z-scores and intervention group. Statistical difference tested with linear regression with 50-74.9 nmol/L applied as a reference group. 25(OH)D, 25-hydroxy vitamin D; SDS, SD-score, based on Finnish sex- and age-specific normative data for infant growth; Length/weight, length-adjusted weight, HC, head circumference; MUAC, mid-upper-arm circumference (in z-score); BMI, body mass index (in z-score). The reference group's symbol has been highlighted.

Figure 5 Toddler 25(OH)D and offspring growth measures at 2 years of age. Symbols present adjusted mean (95% CI) values of growth measures in Toddler 25(OH)D categories of <75 nmol/L (n=138) (reference group), 75-125 nmol/L (n=502) and >125 nmol/L (n=172). Adjustments are for corresponding birth size SDS, maternal and paternal height z-scores and intervention group. Statistical difference tested with linear regression with <75 nmol/L applied as a reference group. 25(OH)D, 25-hydroxy vitamin D; SDS, SD-score, based on Finnish sex- and age-specific normative data for infant growth; Length/weight, length-adjusted weight, HC, head circumference; MUAC, mid-upper-arm circumference (in z-score); BMI, body mass index (in z-score). The reference group's symbol has been highlighted.

Figure 6 Toddler 25(OH)D in quartiles and offspring growth measures at 2 years of age. Symbols present adjusted mean (95% CI) values of growth measures in Toddler 25(OH)D quartiles of 1. quartile (<81.2 nmol/L, n=203) (reference group), 2. quartile (81.2-99.2 nmol/L, n=203), 3. quartile (99.3-120.7 nmol/L, n=204) and 4. quartile (>121 nmol/L, n=202). Adjustments are for corresponding birth size SDS, maternal and paternal height z-scores and intervention group. Statistical difference tested with linear regression with 1. quartile applied as a reference group. 25(OH)D, 25-hydroxy vitamin D; SDS, SD-score, based on Finnish sex- and age-specific normative data for infant growth; Length/weight, length-adjusted weight, HC, head circumference; MUAC, mid-upper-arm circumference; BMI, body mass index. The reference group's symbol has been highlighted.

Table 1 Family characteristics according to intervention groups

	Group-10 n=402	Group-30 n=410	P value
Maternal age, year	31.4 (4.0)	31.9 (4.5)	0.10
Paternal age, year ^a	32.9 (5.0)	33.7 (5.8)	0.026
Maternal height, cm	166.3 (6.1)	166.3 (5.9)	0.94
Paternal height, cm ^b	180.7 (6.7)	180.2 (6.6)	0.36
Maternal prepregnancy BMI ^c	23.2 (3.7)	23.3 (3.7)	0.64
Paternal BMI ^d	26.0 (3.5)	25.6 (3.2)	0.048
Pregnancy 25(OH)D, nmol/L ^e	82.9 (21.9)	81.8 (17.8)	0.49
Pregnancy sampling, gestational week	11.3 (2.2)	11.5 (3.3)	0.39
Maternal supplemental vitamin D intake, µg/d ^d	17.1 (19.8)	14.6 (12.8)	0.26
Maternal smoking, yes, % (n)	15 (61/399)	16 (66/409)	0.74
Paternal smoking, yes, % (n)	26 (102/397)	25 (100/404)	0.76
Parental education, higher, % (n)	81 (322/397)	84 (345/410)	0.26
Family income level ^f			0.24
<40 000 €/year, % (n)	16 (64)	18 (70)	
40 000-89 000 €/year, % (n)	59 (231)	54 (216)	
>90 000 €/year, % (n)	20 (79)	20 (81)	
Don't know	5 (18)	8 (31)	

Values are means (SD) and P values are based on Independent-Samples T test, Mann-Whitney U test or Chi-Square.

^a9 missing values; ^b16 missing values; ^c4 missing values; ^d24 missing values; ^e132 missing values; ^f22 missing values.

Table 2 Infant growth parameters from birth to 2 years of age according to intervention groups

	Group-10 n=402	Group-30 n=410	P value
At birth			
Gestational age, wk	40.1 (1.1)	40.2 (1.1)	0.08
Length, cm	50.3 (1.7)	50.4 (1.8)	0.35
Length, SDS	-0.12 (0.89)	-0.11 (0.92)	0.86
Weight, kg	3.50 (0.37)	3.56 (0.40)	0.027
Weight, SDS	-0.19 (0.79)	-0.12 (0.84)	0.17
Length-adjusted weight, SDS	0.02 (0.93)	0.14 (0.93)	0.08
Head circumference, cm ^a	35.2 (1.4)	35.2 (1.4)	0.45
Head circumference, SDS ^a	0.19 (1.04)	0.08 (1.02)	0.12
UCB 25(OH)D, nmol/L [range] ^b	83.4 (28.2) [36.7-283.7]	81.8 (23.5) [37.8-229.0]	0.39
At 1 year of age			
Age at follow-up, y	1.00 (0.03)	1.00 (0.03)	0.93
Length, cm ^a	75.4 (2.6)	75.2 (2.5)	0.19
Length, SDS ^a	-0.49 (1.0)	-0.59 (0.98)	0.14
Weight, kg	9.8 (1.2)	9.8 (1.1)	0.44
Weight, SDS	-0.19 (1.0)	-0.24 (0.99)	0.48
Length-adjusted weight, SDS ^a	0.04 (1.0)	0.04 (1.0)	0.94
Head circumference, cm ^e	46.6 (1.2)	46.4 (1.2)	0.08
Head circumference, SDS ^e	-0.32 (0.97)	-0.45 (0.93)	0.053
MUAC, mm ^f	152.7 (12.9)	153.0 (11.8)	0.69
MUAC ² , z-score ^f	-0.02 (1.0)	0.02 (0.96)	0.66
Blood 25(OH)D, nmol/L [range] ^g	82.8 (19.9) [37.0-140.0]	116.0 (27.6) [51.8-241.0]	<0.001
Vitamin D intake from food, µg/day ^h	6.3 (3.7)	6.1 (3.7)	0.38
Compliance, % ⁱ	90.1 (10.4)	89.4 (10.6)	0.48
Supplemental vitamin D intake, compliance based µg/day ⁱ	9.0 (1.0)	26.8 (3.2)	<0.001
Energy intake, MJ/day ^h	3.36 (0.9)	3.31 (0.9)	0.26
At 2 years of age			
Age at follow-up, y	1.99 (0.03)	1.99 (0.03)	0.27
Length, cm	87.8 (3.2)	87.7 (3.0)	0.77
Length, SDS	-0.24 (1.04)	-0.27 (1.0)	0.71
Weight, kg ^d	12.5 (1.4)	12.6 (1.4)	0.44
Weight, SDS ^d	-0.19 (0.98)	-0.14 (0.99)	0.47
Length-adjusted weight, SDS ^d	-0.12 (0.98)	-0.02 (0.98)	0.15
Head circumference, cm ^j	49.1 (1.3)	49.1 (1.3)	0.60
Head circumference, SDS ^j	-0.22 (1.0)	-0.26 (0.98)	0.56
MUAC, mm ^k	161.8 (11.2)	162.5 (12.2)	0.42
MUAC, z-score ^k	-0.03 (0.95)	0.03 (1.04)	0.40
BMI, kg/m ² ^d	16.2 (1.2)	16.3 (1.2)	0.15
BMI, z-score ^d	-0.05 (0.99)	0.05 (1.01)	0.14

Blood 25(OH)D, nmol/L [range]	86.5 (19.7) [42.4-153.5]	117.7 (26.1) [56.5-207.4]	<0.001
Compliance, % ^l	86.6 (16.2)	85.5 (17.7)	0.73
Compliance based supplemental vitamin D intake, µg/day ^l	8.7 (1.6)	25.6 (5.3)	<0.001
Duration of breastfeeding, months ^m	10.7 (5.7)	11.0 (5.6)	0.44

Values are means (SD). P values are based on Independent-Samples T test or Mann-Whitney U test. SDS, standard deviation score, based on Finnish sex- and age-specific normative data for infant growth; UCB, umbilical cord blood; 25(OH)D, blood 25-hydroxyvitamin D concentration; MUAC, mid-upper-arm circumference; BMI, body mass index.

^a1 missing value; ^b18 missing values; ^c22 missing values; ^d2 missing values; ^e7 missing values; ^f34 missing values; ^g58 missing values; ^h107 missing values, breast milk intake not included; ⁱ10 values missing; ^j14 missing values; ^k17 missing values; ^l20 values missing; ^m6 values missing, duration of breastfeeding was set to 2 years if still ongoing at 2 years' follow-up

Table 3 Associations between Maternal 25(OH)D concentrations and offspring's growth measures at 2-years' follow-up visit

	SDS				z-score	
	Length	Weight	Length-adjusted weight	Head circumference	MUAC	BMI
Pregnancy 25(OH)D, 10 nmol/L, n=680						
Model 1, unadjusted	-0.01 (-0.05, 0.02)	-0.02 (-0.06, 0.02)	-0.02 (-0.05, 0.02)	-0.00 (-0.04, 0.04)	-0.03 (-0.07, 0.01)	-0.02 (-0.05, 0.02)
P value	0.48	0.29	0.38	0.97	0.12	0.42
Model 2, adjusted ^a	-0.02 (-0.05, 0.02)	-0.02 (-0.06, 0.01)	-0.00 (-0.00, -0.00)	0.00 (-0.02, 0.02)	-0.03 (-0.07, 0.00)	-0.02 (-0.05, 0.02)
P value	0.29	0.16	0.33	0.97	0.11	0.37
UCB 25(OH)D, 10 nmol/L, n=794						
Model 1, unadjusted	0.01 (-0.02, 0.03)	-0.01 (-0.04, 0.02)	-0.02 (-0.05, 0.01)	-0.01 (-0.04, 0.02)	0.00 (-0.02, 0.03)	-0.02 (-0.05, 0.00)
P value	0.67	0.43	0.13	0.40	0.80	0.09
Model 2, adjusted ^a	0.00 (-0.02, 0.03)	-0.01 (-0.03, 0.02)	-0.02 (-0.04, 0.01)	0.01 (-0.02, 0.03)	0.01 (-0.01, 0.02)	-0.02 (-0.04, 0.01)
P value	0.72	0.60	0.24	0.69	0.65	0.19

Values are beta coefficients (95% CI) per 10 nmol/L increase in 25(OH)D concentration based on linear regression.

SDS, standard deviation score, based on Finnish sex- and age-specific normative data for infant growth; 25(OH)D, blood 25-hydroxyvitamin D concentration; MUAC, mid-upper-arm circumference; BMI, body mass index; UCB, umbilical cord blood.

^aModel 2 is adjusted for the corresponding birth size SDS (except for MUAC and BMI; the covariate was length-adjusted birth weight), maternal and paternal height z-scores, and intervention group.

Missing values: in Pregnancy 25(OH)D analyses: 1 value missing in weight, length-adjusted weight and BMI; 12 values missing from head circumference and MUAC, in UCB 25(OH)D analyses: 2 values missing in weight, length-adjusted weight and BMI; 15 values missing from head circumference and MUAC.

Table 4 Associations between Maternal and Toddler 25(OH)D and conditional growth at 2 years' follow-up visit

622

	SD unit				
	Length	Weight	Length-adjusted weight	Head circumference	MUAC
Pregnancy 25(OH)D, 10 nmol/L, n=679					
Model 1, unadjusted	-0.01 (-0.05, 0.03)	0.00 (-0.04, 0.03)	0.01 (-0.03, 0.04)	0.04 (0.00, 0.08)	0.00 (-0.04, 0.03)
P value for linear association	0.64	0.83	0.78	0.036	0.83
Model 2, adjusted ^a	-0.01 (-0.05, 0.03)	0.00 (-0.04, 0.03)	0.01 (-0.03, 0.04)	0.04 (0.00, 0.08)	0.00 (-0.04, 0.03)
P value for linear association	0.65	0.81	0.74	0.037	0.80
UCB 25(OH)D, 10 nmol/L, n=793					
Model 1, unadjusted	0.02 (-0.01, 0.04)	0.00 (-0.03, 0.02)	-0.02 (-0.04, 0.01)	0.03 (0.01, 0.06)	0.01 (-0.01, 0.04)
P value for linear association	0.23	0.74	0.20	0.015	0.30
Model 2, adjusted ^a	0.01 (-0.01, 0.04)	-0.01 (-0.03, 0.02)	-0.02 (-0.04, 0.01)	0.03 (0.01, 0.06)	0.02 (-0.01, 0.04)
P value for linear association	0.27	0.61	0.19	0.014	0.25
Toddler 25(OH)D at 2 years, 10 nmol/L, n=811					
Model 1, unadjusted	0.01 (-0.01, 0.04)	0.02 (0.00, 0.05)	0.01 (-0.01, 0.04)	0.01 (-0.01, 0.04)	-0.01 (-0.03, 0.02)
P value for linear association	0.40	0.072	0.34	0.30	0.59
Model 2, adjusted ^a	0.00 (-0.03, 0.03)	0.01 (-0.02, 0.04)	0.00 (-0.03, 0.03)	0.01 (-0.02, 0.04)	-0.02 (-0.05, 0.01)
P value for linear association	0.82	0.60	0.82	0.48	0.32

623

Values are beta coefficients (95% CI) per 10 nmol/L increase in 25(OH)D concentration based on linear regression. Conditional growth refers to the difference of body size at 2 years with expected based on body size at birth, 6 months and 1 year, expressed in standardized residuals, SD units.

25(OH)D, 25-hydroxyvitamin D concentration; UCB, umbilical cord blood.

^aModel 2 is adjusted for maternal and paternal height z-scores, and intervention group.

Missing values: in Pregnancy 25(OH)D analyses: 1 value missing in length-adjusted weight; 40 values missing from head circumference; 32 values missing from MUAC, in UCB 25(OH)D analyses: 1 value missing in length; 2 values missing length-adjusted weight; 42 values missing from head circumference; 44 values missing from MUAC, in Toddler 25(OH)D analyses: 1 value missing in length-adjusted weight; 2 values missing from length-adjusted weight; 44 values missing from head circumference; 46 values missing from MUAC.

Table 5 Associations between Infant 25(OH)D concentrations and growth measures at 1-year's follow-up visit stratified by intervention group

Infant 25(OH)D, 10 nmol/L	SDS				z-score
	Length	Weight	Length-adjusted weight	Head circumference	MUAC
Group-10, n=371					
Model 1, unadjusted	0.02 (-0.03, 0.07)	0.01 (-0.04, 0.06)	0.00 (-0.05, 0.05)	-0.01 (-0.06, 0.04)	-0.01 (-0.07, 0.04)
P value	0.47	0.69	0.95	0.79	0.68
Model 2, adjusted ^a	0.02 (-0.03, 0.07)	0.02 (-0.03, 0.07)	0.00 (-0.05, 0.06)	0.00 (-0.05, 0.04)	-0.01 (-0.06, 0.05)
P value	0.39	0.54	0.92	0.96	0.77
Group-30, n=383					
Model 1, unadjusted	-0.04 (-0.07, 0.00)	-0.07 (-0.10, -0.03)	-0.06 (-0.10, -0.02)	-0.04 (-0.07, 0.00)	-0.04 (-0.08, 0.00)
P value	0.047	<0.001	0.001	0.039	0.026
Model 2, adjusted ^a	-0.02 (-0.05, 0.01)	-0.05 (-0.09, -0.02)	-0.06 (-0.10, -0.02)	-0.02 (-0.05, 0.01)	-0.04 (-0.08, -0.01)
P value	0.17	0.001	0.001	0.19	0.022

Values are beta coefficients (95% CI) per 10 nmol/L increase in 25(OH)D concentration based on linear regression.

SDS, standard deviation score, based on Finnish sex- and age-specific normative data for infant growth; 25(OH)D, blood 25-hydroxyvitamin D concentration; MUAC, mid-upper-arm circumference.

^aModel 2 is adjusted for the corresponding birth size SDS (except for MUAC; the covariate was length-adjusted birth weight), maternal and paternal height z-scores and intervention group (except in analyses stratified by intervention groups).

Missing values: 1 value missing from length and length-adjusted weight; 5 values missing from head circumference; 32 values missing from MUAC.

Table 6 Associations between Toddler 25(OH)D concentrations and growth measures at 2-years' follow-up visit stratified by intervention group

Toddler 25(OH)D, 10 nmol/L	SDS				z-score	
	Length	Weight	Length-adjusted weight	Head circumference	MUAC	BMI
All, n=812						
Model 1, unadjusted	-0.02 (-0.05, 0.00)	-0.03 (-0.06, -0.01)	-0.03 (-0.05, 0.00)	-0.01 (-0.04, 0.00)	-0.02 (-0.04, 0.01)	-0.03 (-0.06, 0.00)
P value	0.057	0.009	0.040	0.32	0.13	0.035
Model 2, adjusted ^a	-0.03 (-0.05, 0.00)	-0.04 (-0.07, -0.02)	-0.02 (-0.05, 0.00)	-0.00 (-0.02, 0.02)	-0.02 (-0.04, 0.01)	-0.06 (-0.09, -0.02)
P value	0.038^b	0.001	0.001	0.92	0.030	0.001
Group-10, n=402						
Model 1, unadjusted	-0.04 (-0.09, 0.02)	-0.07 (-0.12, -0.02)	-0.06 (-0.11, -0.02)	0.02 (-0.04, 0.07)	-0.03 (-0.08, 0.02)	-0.06 (-0.11, -0.01)
P value	0.16	0.008	0.009	0.56	0.20	0.011
Model 2, adjusted ^a	-0.03 (-0.07, 0.01)	-0.05 (-0.10, -0.01)	-0.06 (-0.11, -0.01)	0.01 (-0.04, 0.06)	-0.02 (-0.07, 0.02)	-0.06 (-0.11, -0.01)
P value	0.19	0.016	0.018	0.68	0.33	0.018
Group-30, n=410						
Model 1, unadjusted	-0.03 (-0.07, 0.01)	-0.05 (-0.09, -0.01)	-0.04 (-0.08, -0.01)	-0.03 (-0.06, 0.01)	-0.04 (-0.08, -0.00)	-0.04 (-0.08, -0.01)
P value	0.12	0.009	0.018	0.15	0.049	0.021
Model 2, adjusted ^a	-0.02 (-0.06, 0.01)	-0.04 (-0.07, 0.00)	-0.04 (-0.06, -0.02)	-0.01 (-0.03, 0.01)	-0.04 (-0.06, -0.02)	-0.04 (-0.07, -0.01)
P value	0.13	0.034	0.027	0.56	0.062	0.032

Values are beta coefficients (95% CI) per 10 nmol/L increase in 25(OH)D concentration based on linear regression.

SDS, standard deviation score, based on Finnish sex- and age-specific normative data for infant growth; 25(OH)D, blood 25-hydroxyvitamin D concentration; MUAC, mid-upper-arm circumference; BMI, body mass index.

^aModel 2 is adjusted for the corresponding birth size SDS (except for MUAC and BMI; the covariate was length-adjusted birth weight), maternal and paternal height z-scores and intervention group.

^bAdditional adjustment for maternal prepregnancy BMI, paternal BMI, parental smoking status, parental education level, family income level, and duration of breastfeeding attenuated the association to P=0.054.

Missing values: 2 values missing from weight, length-adjusted weight and BMI; 14 values missing from head circumference; 17 values missing from MUAC.

Pregnancy 25(OH)D and offspring growth measures at 2 years (n=680)

UCB 25(OH)D and offspring growth measures at 2 years (n=794)

Toddler 25(OH)D and growth measures at 2 years (n=812)

Toddler 25OHD at 2 years in quartiles (n=812)